Suzhou Fushilai Pharmaceutical Co. Ltd. Working Capital to Net Assets Ratio
Suzhou Fushilai Pharmaceutical Co. Ltd. working capital to net assets ratio. Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has a Working Capital to Net Assets ratio of 74.9% as of June 2025. Working capital of CN¥1.44 Billion (current assets of CN¥1.59 Billion minus current liabilities of CN¥153.70 Million) is measured against net assets of CN¥1.92 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
Working capital to net assets ratio of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024. This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 74.9%, reflecting working capital of CN¥1.44 Billion against net assets of CN¥1.92 Billion CNY. See Suzhou Fushilai Pharmaceutical Co. Ltd. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Suzhou Fushilai Pharmaceutical Co. Ltd. Working Capital to Net Assets Ratio by Year (2019–2024)
Suzhou Fushilai Pharmaceutical Co. Ltd. working capital to net assets ratio by year from 2019 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Suzhou Fushilai Pharmaceutical Co. Ltd..
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 77.7% | CN¥1.47 Billion | CN¥1.89 Billion | CN¥1.61 Billion | CN¥145.25 Million | ▼ -1.3 pp |
| 2023 | 79.0% | CN¥1.54 Billion | CN¥1.95 Billion | CN¥1.65 Billion | CN¥112.10 Million | ▼ -0.5 pp |
| 2022 | 79.5% | CN¥1.50 Billion | CN¥1.89 Billion | CN¥1.65 Billion | CN¥149.91 Million | ▲ +33.3 pp |
| 2021 | 46.2% | CN¥343.43 Million | CN¥742.84 Million | CN¥516.60 Million | CN¥173.17 Million | ▲ +4.2 pp |
| 2020 | 42.1% | CN¥262.00 Million | CN¥622.64 Million | CN¥372.98 Million | CN¥110.98 Million | ▼ -1.9 pp |
| 2019 | 44.0% | CN¥256.18 Million | CN¥581.96 Million | CN¥380.88 Million | CN¥124.70 Million | — |